Estados Unidos - inglés - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride in 5% dextrose injection, usp is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. when indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. poor perfusion of vital organs: although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 ml/minute prognosis is more favorable. however, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. the drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. low cardiac output: dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. increased output has been associated with unchanged or decreased systemic vascular resistance (svr). the association of static or decreased svr with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension: low to moderate doses of dopamine, which have little effect on svr, can be used to manage hypotension due to inadequate cardiac output. at high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished svr. as in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. dopamine hydrochloride should not be used in patients with pheochromocytoma. dopamine should not be administered in the presence of uncorrected tachyarrhythmias or ventricular fibrillation. to open tear outer wrap at notch and remove solution container. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. preparation for administration (use aseptic technique) 1. close flow control clamp of administration set. 2. remove cover from outlet port at bottom of container. 3. insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. note: see full directions on administration set carton. 4. suspend container from hanger. 5. squeeze and release drip chamber to establish proper fluid level in chamber. 6. open flow control clamp and clear air from set. close clamp. 7. attach set to venipuncture device. if device is not indwelling, prime and make venipuncture. 8. regulate rate of administration with an infusion pump, preferably a volumetric pump. warning: do not use flexible container in series connections.

Países Bajos - neerlandés - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

hikma farmaceutica (portugal), s.a. estrada do rio da mó, 8, 8a e 8b fervenca 2705-906 terrugem snt (portugal) - dopamine hydrochloride 40 mg/ml samenstelling overeenkomend met ; dopamine 32,3 mg/ml - concentraat voor oplossing voor infusie - natriumchloride ; natriummetabisulfiet (e 223) ; stikstof (head space) (e 941) ; water voor injectie ; zoutzuur (e 507), - dopamine

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - dopamine hydrochloride - concentrate for solution for infusion - 40 milligram(s)/millilitre - adrenergic and dopaminergic agents; dopamine

Estados Unidos - inglés - NLM (National Library of Medicine)

deseret biologicals, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride - headache, reading difficulty, poor memory • for the temporary relief of symptoms including: • headache • reading difficulty • poor memory these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - dopamine hydrochloride - concentrate for solution for infusion - 160 milligram(s)/millilitre - dopamine

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - dopamine hydrochloride - solution for infusion - 40mg/1ml

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - dopamine hydrochloride - solution for infusion - 40mg/1ml

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - dopamine hydrochloride - solution for infusion - 40mg/1ml

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - dopamine hydrochloride - solution for infusion - 160mg/1ml

Estados Unidos - inglés - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. clinical studies have shown that when dopamine hcl is administered before urine flow has diminished to levels of approximately 0.3 ml/minute, prognosis is more favorable. nevertheless, in a number of oliguric or anuric patients, administration of dopamine hcl has resulted in an increase in urine flow, which in some cases reached normal levels. dopamine hcl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. it should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. low cardiac output – increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. increase in cardiac output has been associated with either static or decreased systemic vascular resistance (svr). static or decreased svr associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension – hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine hcl which have little effect on svr. at high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished svr. as in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. therefore, it is suggested that the physician administer dopamine hcl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. dopamine hcl should not be used in patients with pheochromocytoma. dopamine hcl should not be administered to patients with uncorrected tachyarrhythmias or ventricular fibrillation.